Literature DB >> 20018265

Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.

André van Maurik1, Nicolas Sabarth, Helga Savidis Dacho, Peter Brühl, Michael Schwendinger, Brian A Crowe, P Noel Barrett, Otfried Kistner, M Keith Howard.   

Abstract

Recent findings indicate that seasonal influenza vaccination or infection of healthy humans may contribute to heterosubtypic immunity against new influenza A subtypes, such as H5N1. Here, we investigated whether seasonal influenza vaccination in a mouse model could induce any immunity against the H5N1 subtype. It could be demonstrated that, largely due to the H1N1 component strain A/NewCaledonia/20/99, parenteral immunization of mice with a trivalent seasonal influenza vaccine elicited heterosubtype H5-reactive antibodies able to confer partial protection against H5N1 influenza virus infection. Furthermore, the trivalent seasonal influenza vaccine was found to be compatible with a whole virus H5N1 vaccine in a heterologous prime-boost immunization regimen, achieving superior efficacy compared to a single immunization with an equivalent low-dose of the H5N1 vaccine. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018265     DOI: 10.1016/j.vaccine.2009.12.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.

Authors:  Glendie Marcelin; Hilliary M Bland; Nicholas J Negovetich; Matthew R Sandbulte; Ali H Ellebedy; Ashley D Webb; Yolanda S Griffin; Jennifer L DeBeauchamp; Janet E McElhaney; Richard J Webby
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

2.  M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.

Authors:  Yasuko Hatta; David Boltz; Sally Sarawar; Yoshihiro Kawaoka; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2017-06-28       Impact factor: 3.641

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.

Authors:  Steven Rockman; Lorena E Brown; Ian G Barr; Brad Gilbertson; Sue Lowther; Anatoly Kachurin; Olga Kachurina; Jessica Klippel; Jesse Bodle; Martin Pearse; Deborah Middleton
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

Review 5.  Cross-protective immune responses elicited by live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

6.  Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance.

Authors:  Danuta M Skowronski; Marie-Eve Hamelin; Naveed Z Janjua; Gaston De Serres; Jennifer L Gardy; Chantal Rhéaume; Xavier Bouhy; Guy Boivin
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

7.  A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.

Authors:  Haiyan Chang; Chaoyang Huang; Jian Wu; Fang Fang; Wenjie Zhang; Fuyan Wang; Ze Chen
Journal:  Virol J       Date:  2010-08-21       Impact factor: 4.099

8.  Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.

Authors:  Heng Ding; Cheguo Tsai; Fan Zhou; Philippe Buchy; Vincent Deubel; Paul Zhou
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

9.  T cell mediated immunity against influenza H5N1 nucleoprotein, matrix and hemagglutinin derived epitopes in H5N1 survivors and non-H5N1 subjects.

Authors:  Pirom Noisumdaeng; Thaneeya Roytrakul; Jarunee Prasertsopon; Phisanu Pooruk; Hatairat Lerdsamran; Susan Assanasen; Rungrueng Kitphati; Prasert Auewarakul; Pilaipan Puthavathana
Journal:  PeerJ       Date:  2021-03-10       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.